Histogen Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-12-17: Form 8-K; Period of report 2020-12-17; Description 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 7.01.
- 2020-12-01: Form 8-K; Period of report 2020-12-01; Description 8.01 Other Events; Details 8.01.
- 2020-11-16: Form 8-K; Period of report 2020-11-16; Description 8.01 Other Events; Details 8.01.
- 2020-11-12: Form 8-K; Period of report 2020-11-11; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2020-12-17 | 8-K | 2020-12-17 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 Executive management of Histogen Inc. (the “Company”) will be presenting an updated corporate presentation at various upcoming meetings on or after December 17, 2020. 8.01 On December 17, 2020, the Company issued a news release announcing that it filed for an investigational new drug (IND) from the United States Food and Drug Administration (FDA) to initiate a Phase 1/2 clinical trial of HST-003 for regeneration of cartilage in the knee. | d67504d8k.htm |
| 2020-12-01 | 8-K | 2020-12-01 | 8.01 Other Events | 8.01 On December 1, 2020, Histogen Inc. issued a news release announcing preliminary week 18 results from its Phase 1b/2a clinical trial of HST-001 in male patients with androgenic alopecia. | d69769d8k.htm |
| 2020-11-16 | 8-K | 2020-11-16 | 8.01 Other Events | 8.01 On November 16, 2020, Histogen Inc. (the “Company”) issued a press release announcing the closing of its previously announced registered direct offering for the issuance and sale of 2,522,784 shares of its common stock, at a purchase price of $1.78375 per share. | d75820d8k.htm |
| 2020-11-12 | 8-K | 2020-11-11 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 The information contained above in Item 1.01 related to the Warrants and the Placement Agent Warrants and the shares of Common Stock issuable thereunder is hereby incorporated by reference into this Item 3.02. 8.01 On November 12, 2020, the Company issued a press release regarding the transactions described above under Item 1.01 of this Current Report on Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | d36524d8k.htm |
| 2020-11-10 | 8-K | 2020-11-10 | 2.02 Results of Operations and Financial Condition | hsto-8k_20201110.htm | |
| 2020-10-27 | 8-K | 2020-10-26 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On October 27, 2020, the Company issued a press release announcing the transaction with Amerimmune. | d92015d8k.htm |
| 2020-09-29 | 8-K | 2020-09-29 | 8.01 Other Events | 8.01 On September 29, 2020, Histogen Inc. (the “Company”) issued a news release announcing an update for its HST-002 dermal filler program and other programs. | d51132d8k.htm |
| 2020-08-27 | 8-K | 2020-08-27 | 8.01 Other Events | 8.01 On August 17, 2020, Histogen Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a shelf registration statement on Form S-3, as amended (File No. 333-248074), which was declared effective by the SEC on August 26, 2020, and which replaced the Company’s previous shelf registration statement on Form S-3 (File No. 333-220014) filed with the SEC on August 17, 2017. | d17219d8k.htm |
| 2020-08-13 | 8-K | 2020-08-13 | 2.02 Results of Operations and Financial Condition | hsto-8k_20200813.htm | |
| 2020-08-07 | 8-K | 2020-08-07 | 7.01 Regulation FD Disclosure | 7.01 Executive management of Histogen Inc. will be presenting an updated corporate presentation at various upcoming meetings on or after August 7, 2020. | d41143d8k.htm |
| 2020-07-20 | 8-K | 2020-07-20 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 1.02 The Company elected to terminate the At Market Issuance Sales Agreement, dated August 2, 2018, between the Company and Stifel, Nicolaus & Company, Incorporated Company effective as of July 20, 2020. 8.01 On July 20, 2020, the Company issued a press release announcing the transaction with Lincoln Park. | d51427d8k.htm |
| 2020-06-26 | 8-K/A | 2020-05-26 | 9.01 Financial Statements and Exhibits | 9.01 (a) Financial statements of business acquired. | d879834d8ka.htm |
| 2020-06-05 | 8-K | 2020-06-05 | 7.01 Regulation FD Disclosure | 7.01 Executive management of Histogen Inc. will be presenting an updated corporate presentation at various upcoming meetings on or after June 5, 2020. | d938089d8k.htm |
| 2020-06-01 | 8-K | 2020-05-26 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On May 26, 2020, Conatus Pharmaceuticals, Inc. (“Conatus”) completed its business combination with the Delaware corporation that was previously known as “Histogen Inc.” in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of January 28, 2020 (the “Merger Agreement”), by and among Conatus, Chinook Merger Sub, Inc. (“Merger Sub”), and Histogen Inc.(“Histogen”), pursuant to which Merger Sub merged with and into Histogen, with Histogen surviving as a wholly-owned subsidiary of Conatus (the “Merger”). | d830291d8k.htm |
| 2020-05-28 | 8-K | 2020-05-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 The Board of Directors (the “Board”) of Histogen, Inc. (“Histogen”) appointed Susan A. Knudson as Executive Vice President and Chief Financial Officer of Histogen, effective as of May 27, 2020 (the “Effective Date”). 8.01 Histogen’s press release, dated May 28, 2020, announcing the appointment of Ms. Knudson as Histogen’s Chief Financial Officer is furnished as Exhibit 99.1 to this report. | d929666d8k.htm |
| 2020-05-27 | 8-K | 2020-05-26 | 2.01 Completion of Acquisition or Disposition of Assets; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 2.01 On May 26, 2020, Conatus Pharmaceuticals, Inc. (the “Company”) completed its business combination with the Delaware corporation that was previously known as “Histogen Inc.” in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of January 28, 2020 (the “Merger Agreement”), by and among the Company, Chinook Merger Sub, Inc. (“Merger Sub”), and Histogen Inc.(“Histogen”), pursuant to which Merger Sub merged with and into Histogen, with Histogen surviving as a wholly-owned subsidiary of the Company (the “Merger”). 3.03 On May 26, 2020, in connection with the Merger, the Company effected the Reverse Stock Split by the filing of a Certificate of Amendment (the “Reverse Stock Split Certificate”) with the Secretary of State of the State of Delaware pursuant to the Delaware General Corporation Law. 5.01 The information set forth in Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01. 5.02 from the Board and any respective committee of the Board to which they belonged, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. 5.03 The information set forth in Item 3.03 of this Current Report on Form 8-K is incorporated by reference into this Item 5.03. | d925005d8k.htm |
| 2020-05-21 | 8-K | 2020-05-21 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 21, 2020, Conatus Pharmaceuticals Inc. (the “Company”) reconvened its Special Meeting of Stockholders (the “Special Meeting”), which was previously convened and adjourned on May 7, 2020. | d932971d8k.htm |
| 2020-05-07 | 8-K | 2020-05-07 | 8.01 Other Events | 8.01 On May 7, 2020, Conatus Pharmaceuticals Inc. (the “Company” or “Conatus”) convened and adjourned a special meeting of stockholders because a quorum was not present to conduct business at the special meeting. | d842676d8k.htm |
| 2020-05-01 | 8-K | 2020-05-01 | 2.02 Results of Operations and Financial Condition | 2.02 On May 1, 2020, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter ended March 31, 2020. | f8k_043020.htm |
| 2020-03-30 | 8-K | 2020-03-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | cnat-8k_20200330.htm |
| 2020-03-11 | 8-K | 2020-03-11 | 2.02 Results of Operations and Financial Condition | 2.02 On March 11, 2020, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2019. | f8k_031120.htm |
| 2020-01-28 | 8-K | 2020-01-28 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 5.02 On January 27, 2020, Conatus entered into an amendment to the employment agreement with each of Steven J. Mento, Ph.D., its President and Chief Executive Officer, Keith W. Marshall, Ph.D., M.B.A., its Executive Vice President, Chief Operating Officer and Chief Financial Officer, and Alfred P. Spada, its Executive Vice President, Research and Development and Chief Scientific Officer (the “Amendment to Employment Agreements”). 7.01 On January 28, 2020, Conatus issued a joint press release with Histogen announcing their entry into the Merger Agreement described above under Item 1.01. | d875852d8k.htm |